Walgreens introduced this week that it’s increasing its specialty pharmacy choices to incorporate cell and gene remedy providers. The transfer might permit Walgreens to play an even bigger position in a rising market. Analysis exhibits that specialty medicine now account for greater than half of the nation's prescription drug spending, regardless of making up solely a small proportion of whole prescriptions.

With the announcement, the pharmacy large launched a newly built-in enterprise unit referred to as Walgreens Specialty Pharmacy. The unit consists of most of Walgreens' specialty pharmacy belongings, together with specialty pharmacy subsidiary AllianceRx.

This unit will fall underneath Walgreens' core division. Then again, Defend Well being Options – Walgreens' subsidiary that helps pharmacies within the healthcare system – will stay underneath Walgreens' US healthcare division.

As a brand new enterprise unit, Walgreens Specialty Pharmacy will embody a 200,000-square-foot innovation middle in Pittsburgh, practically 300 neighborhood specialty pharmacies, 4 central specialty pharmacies and greater than 1,500 specialty skilled pharmacists. In response to Walgreens' press launch, the unit additionally has a rising variety of 240 drugs with restricted distribution.

Trade consultants weren't shocked by Walgreens' announcement, saying it is smart for a significant pharmacy firm to wish to deepen its presence within the fastest-growing phase of drug spending.

Pleasure Liu – CEO of Plenful, an organization that gives pharmacy automation instruments – famous that the healthcare business is evolving and that Walgreens, like every other healthcare firm, wants progressive methods to remain aggressive.

“Specialty pharmacy providers are profitable and in excessive demand given medical advances and an growing older inhabitants,” she wrote in an electronic mail. “That is an thrilling step for each Walgreens and the sufferers of their care.”

By increasing its specialty pharmacy providers, Walgreens can diversify its choices. This might result in the corporate bettering its worth proposition and relationships with sufferers, payers, suppliers and pharmacy profit managers, Liu defined.

She stated success will depend upon how properly Walgreens can “align the targets of all enterprise items and use one of the best instruments to streamline workflows and obtain development.”

One other business chief — Rick Ratliff, CEO of MedAdvisor Options, which supplies affected person engagement options to pharmacies — stated he wasn't stunned by Walgreens' announcement, given the corporate's large scale and the spectacular variety of individuals it reaches each day.

“Walgreens may be very properly positioned to assist sufferers acquire quicker entry to specialty drugs, which may have a major optimistic affect on healthcare outcomes,” he acknowledged.

Many individuals prescribed specialty drugs need to undergo an advanced course of to even get their treatment, Ratliff famous. This course of typically consists of prior authorization, verifying profit protection, and figuring out monetary support choices.

This implies specialty pharmacy providers will not be all the time accessible to the sufferers who want them, Ratliff explains.

“If individuals have the flexibility to undergo these processes [a brand] figuring out and trusting them, like Walgreens, considerably will increase the worth proposition for these people – along with the truth that they’re extra prone to enter remedy and achieve success of their treatment journey,” he stated.

Like Ratliff and Liu, Coresight Analysis CEO Deborah Weinswig additionally thinks Walgreens' choice to delve deeper into the specialty pharmacy market might yield a number of strategic advantages.

Coming into this market gives important income alternatives as a result of larger revenue margins related to specialty medicine in comparison with conventional medicine, she identified.

“Given the current challenges some are encountering within the M&An area, launching versus buying could also be one of the best route at the moment,” Weinswig wrote in an electronic mail. “Once we take a look at traits inside healthcare, there’s a clear shift in direction of offering extra built-in healthcare options.”

She famous that this growth will permit Walgreens to higher compete with key business gamers which have already established specialty pharmacy providers, similar to CVS and Cigna's Categorical Scripts.

Walgreens' transfer might additionally assist the corporate diversify its buyer base, Weinswig added. By providing specialty pharmacy providers, Walgreens might place itself to each retain present prospects and appeal to new prospects who want these advanced therapies, she defined.

And Weinswig believes Walgreens' growth into the specialty pharmacy phase will seemingly affect some broader business traits.

She thinks the addition of Walgreens to the specialty pharmacy market might intensify competitors, resulting in extra aggressive costs and higher high quality of service. Elevated competitors might put stress on smaller specialty pharmacies, probably resulting in consolidation inside this area of interest of the market, Weinswig identified.

She additionally predicted {that a} extra aggressive specialty pharmacy market might spur improvements in treatment administration and affected person care applications – which might enhance therapy outcomes for sufferers and enhance the effectivity of the bigger healthcare ecosystem.

“Walgreens' transfer to ascertain a specialty pharmacy enterprise is a strategic initiative that not solely seeks to capitalize on a profitable phase, but in addition positions the corporate for larger competitiveness and buyer engagement inside the evolving healthcare panorama,” Weinswig wrote. “This growth is poised to have profound implications for the sector, fostering aggressive dynamics, fostering innovation and probably catalyzing market consolidation.”

Picture: Joe Raedle, Getty Pictures